Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure

Abstract MYH9-related disorder (MYH9-RD) is autosomal dominant thrombocytopenia caused by mutations in the MYH9 gene, which codes for the non-muscle myosin-IIA heavy chain. We present a case of a 24-year-old Chinese man with MYH9-RD who was initially misdiagnosed with immune thrombocytopenia. Whole-exome sequencing and Sanger sequencing revealed a novel missense mutation in the MYH9 gene at the position of c.4550 G > T (p.G1517V) in exon 32. The same phenotype was observed in the proband, his mother, and his brother, in addition to macrothrombocytopenia and Dohle-like bodies in neutrophil granulocytes without non-hematologic manifestations. Following failed treatment with eltrombopag, avatrombopag, which was not mentioned before in the MYH9-RD treatment, was administered to the patient, and thrombocytopenia improved. In this case report, we present a novel pathogenic mutation and show the potential of avatrombopag for temporarily increasing the platelet count in patients with MYH9-RD.

[1]  D. Kuter.  The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. , 2021, Blood reviews.

[2]  A. Markham.  Avatrombopag: A Review in Thrombocytopenia , 2021, Drugs.

[3]  Feihong Huang,et al.  Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial , 2021, Frontiers in Pharmacology.

[4]  J. Bubalo,et al.  Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists , 2021, Drugs.

[5]  Eun-Ju Lee,et al.  Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists , 2021, American journal of hematology.

[6]  J. González-Porras,et al.  Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia , 2021, International journal of molecular sciences.

[7]  P. Gresele,et al.  Eltrombopag in preparation for surgery in patients with severe MYH9‐related thrombocytopenia , 2019, American journal of hematology.

[8]  A. Savoia,et al.  MYH9: Structure, functions and role of non-muscle myosin IIA in human disease. , 2018, Gene.

[9]  M. Shirley.  Avatrombopag: First Global Approval , 2018, Drugs.

[10]  Nicole Schlegel,et al.  Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders , 2014, Molecular genetics & genomic medicine.

[11]  M. Ballmaier,et al.  MYH9‐Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype–Phenotype Correlations , 2014, Human mutation.

[12]  P. Noris,et al.  Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome , 2012, PloS one.

[13]  P. Noris,et al.  Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. , 2010, Blood.

[14]  P. Noris,et al.  Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder , 2010, Thrombosis and Haemostasis.

[15]  T. Nakahata,et al.  AKR‐501 (YM477) a novel orally‐active thrombopoietin receptor agonist , 2009, European journal of haematology.

[16]  J. Luengo,et al.  Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist , 2009, Stem cells.

[17]  Joseph E Italiano,et al.  Dynamic Visualization of Thrombopoiesis Within Bone Marrow , 2007, Science.

[18]  V. Broudy,et al.  AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. , 2004, Cytokine.

[19]  R. Ravazzolo,et al.  MYH9-Related Disease: May-Hegglin Anomaly, Sebastian Syndrome, Fechtner Syndrome, and Epstein Syndrome Are not Distinct Entities but Represent a Variable Expression of a Single Illness , 2003, Medicine.

[20]  Toshihiro Tanaka,et al.  Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). , 2001, Blood.

[21]  M. Kelley,et al.  Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. , 2000, American journal of human genetics.

[22]  U Magrini,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. , 2000, Nature genetics.